CoCo debuts to develop AD therapeutics

CoCo Therapeutics Ltd. (Oxford, U.K) debuted with undisclosed funding from Advent Venture Partners to develop retinoic acid receptor alpha (RARA) agonists to treat Alzheimer's disease. Founding Chairman Raj Parekh, general partner at Advent, said CoCo is conducting late-stage preclinical work of an undisclosed lead compound, but declined to say when the newco plans to start Phase I testing. ...